181.55

2.37% -4.40

Pre-market: 181.26 -0.29 -0.16%

Astrazeneca Plc (AZN)

Overview News Price History Option Chain Why AZN Down? Discussions Forecast Stock Split Dividend History

Astrazeneca Plc stock is traded at $181.55, with a volume of 2.04M. It is down -2.37% in the last 24 hours and down -0.71% over the past month. A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.

Previous Close:

$185.95

Open:

$184.16

24h Volume:

2.04M

Relative Volume:

1.06

Market Cap:

$281.56B

Revenue:

$60.48B

Net Income/Loss:

$10.40B

P/E Ratio:

54.52

EPS:

3.3297

Net Cash Flow:

$8.05B

1W Performance:

+1.02%

1M Performance:

-0.71%

6M Performance:

+98.89%

1Y Performance:

+149.11%

1-Day Range:

$181.36

$185.31

1-Week Range:

$174.60

$186.12

52-Week Range:

$68.61

$212.71

Astrazeneca Plc Stock (AZN) Company Profile

Name

Astrazeneca Plc

Sector

Healthcare (1100)

Industry

Drug Manufacturers - General (20)

Phone

Address

Employee

96,100

Twitter

@AstraZeneca

Next Earnings Date

2026-04-29

Latest SEC Filings

AZN's Discussions on Twitter

Compare AZN vs LLY, JNJ, ABBV, MRK

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AZN Astrazeneca Plc	181.55	288.38B	60.48B	10.40B	8.05B	3.3297
LLY Lilly Eli Co	1,149.15	1.01T	72.25B	25.28B	10.37B	27.78
JNJ Johnson Johnson	232.16	560.33B	96.36B	21.04B	17.80B	8.6488
ABBV Abbvie Inc	223.07	401.47B	62.82B	3.60B	19.98B	2.0274
MRK Merck Co Inc	119.52	298.33B	65.51B	8.93B	14.12B	3.5532

Astrazeneca Plc Stock (AZN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-27-26	Initiated	Citigroup	Buy
Oct-27-25	Resumed	Jefferies	Buy
Oct-16-25	Downgrade	Deutsche Bank	Hold → Sell
Apr-15-25	Initiated	Exane BNP Paribas	Outperform
Feb-13-25	Upgrade	UBS	Neutral → Buy
Feb-12-25	Initiated	Morgan Stanley	Overweight
Nov-20-24	Upgrade	UBS	Sell → Neutral
Nov-06-24	Upgrade	Deutsche Bank	Sell → Hold
Sep-13-24	Downgrade	Deutsche Bank	Hold → Sell
May-30-24	Initiated	Goldman	Buy
Apr-16-24	Upgrade	Deutsche Bank	Sell → Hold
Feb-08-24	Downgrade	Deutsche Bank	Hold → Sell
Jan-23-24	Initiated	Morgan Stanley	Overweight
Jan-16-24	Resumed	UBS	Sell
Jan-03-24	Downgrade	Jefferies	Buy → Hold
Dec-18-23	Initiated	HSBC Securities	Buy
Sep-25-23	Upgrade	Jefferies	Hold → Buy
Jul-14-23	Initiated	HSBC Securities	Buy
Jul-12-23	Upgrade	UBS	Neutral → Buy
Jul-05-23	Downgrade	Deutsche Bank	Buy → Hold
Apr-11-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jan-05-23	Initiated	BMO Capital Markets	Outperform
Sep-15-22	Downgrade	Credit Suisse	Outperform → Neutral
Sep-07-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Aug-29-22	Upgrade	Argus	Hold → Buy
Jun-14-22	Downgrade	UBS	Buy → Neutral
Feb-11-22	Upgrade	DZ Bank	Sell → Hold
Dec-07-21	Downgrade	Jefferies	Buy → Hold
Aug-12-21	Resumed	JP Morgan	Overweight
Apr-12-21	Downgrade	Argus	Buy → Hold
Mar-16-21	Upgrade	Jefferies	Hold → Buy
Feb-25-21	Upgrade	UBS	Neutral → Buy
Jan-15-21	Initiated	Deutsche Bank	Buy
Dec-07-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-30-20	Upgrade	UBS	Sell → Neutral
Nov-11-20	Upgrade	HSBC Securities	Reduce → Hold
Sep-29-20	Initiated	Berenberg	Buy
Nov-22-19	Initiated	SVB Leerink	Outperform
Oct-25-19	Upgrade	Liberum	Hold → Buy
Apr-02-19	Downgrade	UBS	Neutral → Sell
Feb-05-19	Initiated	Exane BNP Paribas	Outperform
Jan-25-19	Upgrade	Shore Capital	Hold → Buy
Dec-11-18	Resumed	Jefferies	Hold
Oct-09-18	Initiated	Guggenheim	Buy
Aug-16-18	Downgrade	Jefferies	Buy → Hold
Mar-19-18	Upgrade	Jefferies	Hold → Buy
Feb-06-18	Reiterated	Leerink Partners	Mkt Perform
Feb-05-18	Reiterated	Bernstein	Outperform
Jan-18-18	Reiterated	Leerink Partners	Mkt Perform
Dec-29-17	Upgrade	JP Morgan	Neutral → Overweight
Oct-16-17	Upgrade	Credit Suisse	Neutral → Outperform
Sep-25-17	Upgrade	Exane BNP Paribas	Neutral → Outperform
Sep-22-17	Upgrade	Bernstein	Mkt Perform → Outperform

View All

Astrazeneca Plc Stock (AZN) Latest News

05:02 AM

AstraZeneca Advances Obesity, Diabetes Medication Elecoglipron to Phase 3 Trial - marketscreener.com

05:02 AM

04:29 AM

ASTRAZENECA : Deutsche Bank reiterates its Sell rating - marketscreener.com

04:29 AM

03:55 AM

BofA reiterates Buy on AstraZeneca stock, cites adjuvant trial outlook By Investing.com - Investing.com South Africa

03:55 AM

03:09 AM

AstraZeneca progresses elecoglipron after positive phase IIb results - London South East

03:09 AM

02:02 AM

Why is CAMBRIA-1 emerging as AstraZeneca’s key breast cancer catalyst? - Investing.com UK

02:02 AM

01:58 AM

ASTRAZENECA : Jefferies remains its Buy rating - marketscreener.com

01:58 AM

Jun 08, 2026

AstraZeneca unveils data behind Phase III-bound oral GLP-1 - FirstWord Pharma

Jun 08, 2026

AstraZeneca’s oral GLP-1 advances to Phase III after strong trial results - Investing.com Nigeria

Jun 08, 2026

AstraZeneca obesity pill shows 10.5% weight loss in trial By Investing.com - Investing.com UK

Jun 08, 2026

AstraZeneca : Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme and unlocks next chapter in AstraZeneca’s cardiometabolic and kidney portfolio - marketscreener.com

Jun 08, 2026

AstraZeneca obesity pill helps patients lose 10.5% of body weight in trial - marketscreener.com

Jun 08, 2026

AstraZeneca advances weight-loss pill to take aim at obesity leaders - Financial Times

Jun 08, 2026

Astra Obesity Pill Delivers 11.8% Weight Loss in Mid-Stage Trial - Bloomberg

Jun 08, 2026

AstraZeneca plc stock (GB0009895292): Oncology pipeline, obesity push and latest trial updates in fo - AD HOC NEWS

Jun 08, 2026

AstraZeneca Reports Significant Proteinuria Reduction With Ultomiris In Rare Kidney Disease - Benzinga

Jun 08, 2026